Skip to content

Bausch + Lomb BLCO Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$55.6M-1,638%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$1.49M-13.2%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$278K-21.9%
Organon logo
OrganonOGN
-$12M+40.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's other noncash income (expense)?
Bausch + Lomb (BLCO) reported other noncash income (expense) of $0 in Q1 2026.
How has Bausch + Lomb's other noncash income (expense) changed year-over-year?
Bausch + Lomb's other noncash income (expense) decreased by 100.0% year-over-year, from $1M to $0.
What does other noncash income (expense) mean?
This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.